RecruitingPhase 1NCT06452316

Study to Evaluate the Safety and Efficacy of CSB-001 Ophthalmic Solution 0.1% in Subjects With Limbal Stem Cell Deficiency

Studying Limbal stem cell deficiency

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Claris Biotherapeutics, Inc.
Intervention
CSB-001 Ophthalmic Solution 0.1%(biological)
Enrollment
65 target
Eligibility
18 years · All sexes
Timeline
20242026

Study locations (6)

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT06452316 on ClinicalTrials.gov

Other trials for Limbal stem cell deficiency

Additional recruiting or active studies for the same condition.

See all trials for Limbal stem cell deficiency

← Back to all trials